Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2018
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms PoCKET
- 22 Nov 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2019.
- 22 Nov 2018 Status changed from not yet recruiting to recruiting.
- 06 Mar 2018 New trial record